GENE ONLINE|News &
Opinion
Blog

2022-06-14| In-Depth

Ushering In A New Generation Of AI-Focused Investments Opportunities

by Reed Slater
Share To

Artificial intelligence (AI) has officially enamored the world with its plethora of potential applications. Optimistic folks see AI as a tool with the power to aid humanity and the technological revolution we live in. AI in the biotech sphere centers around drug discovery and drug repurposing. With a record number of AI-focused biotech companies forming, it is time to consider the applications, limitations, and the prospective future that investors face when confronted with AI startups looking for funding.

At the Digital Redefining Early Stage Investments (RESI) 2022 conference, Bill Kuziel, Ph.D. of MedPro Investors, sits down with three venture capital professionals to discuss the use of AI in biotechnology and its future during uncertain economic times. 

 

 

It's free! Log in now to read

LATEST
Finnish Study Finds Brain Biomarkers for Alzheimer’s Detectable in Middle Age
2025-07-14
Blood Test Developed at Medical University of Vienna Predicts Multiple Sclerosis Risk Years Before Symptoms
2025-07-14
University of Tokyo Researchers Develop In Vivo System to Study Senescent Cells in Aging
2025-07-14
Relmada Therapeutics Ends Development of Depression Drug Esmethadone and Terminates Licensing Agreement
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton in Narcolepsy Treatment
2025-07-14
Takeda Pharmaceuticals Reports Positive Phase 3 Trial Results for Narcolepsy Drug Targeting Daytime Sleepiness and Cataplexy
2025-07-14
Takeda Reports Positive Phase 3 Trial Results for Oveporexton Targeting Orexin Proteins in Narcolepsy Treatment
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top